ArticleGenes & development2017
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.
Open access · diamondAbstract read
In one paragraph
Article in Genes & development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- T1 mapping-based multi-parametric MRI for subtyping and differentiation grading of non-small cell lung cancer.Quantitative imaging in medicine and surgery · 2026Article
- RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations.Cell reports. Medicine · 2025Article
- Tissue stiffness heterogeneity in the jaw and temporomandibular joint: its impact on tumor metabolism and considerations forFrontiers in physiology · 2025Review
- Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).Journal for immunotherapy of cancer · 2024Article
- The value of multiple diffusion metrics based on whole-lesion histogram analysis in evaluating the subtypes and proliferation status of non-small cell lung cancer.Frontiers in oncology · 2024Article
- The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer.Medicina (Kaunas, Lithuania) · 2023Review
- RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.Thoracic cancer · 2023Article
- RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.EMBO molecular medicine · 2023Article
- The road of NSCLC stem cells toward bone metastases.Bone reports · 2022Article
- Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases.Journal of clinical medicine · 2022Article
- Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review.Frontiers in immunology · 2022Article
- Application of diffusion kurtosis imaging andFrontiers in oncology · 2022Article
- Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors.Journal of thoracic disease · 2021Article
- Discovery of the RANKL/RANK/OPG system.Journal of bone and mineral metabolism · 2021Review
- Role of RANKL in cancer development and metastasis.Journal of bone and mineral metabolism · 2021Review
- HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.Cancer research · 2020Article
- Serum extracellular vesicles expressing bone activity markers associate with bone loss after HIV antiretroviral therapy.AIDS (London, England) · 2020Article
- Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.Frontiers in oncology · 2020Review
- Involvement of the Estrogen and Progesterone Axis in Cancer Stemness: Elucidating Molecular Mechanisms and Clinical Significance.Frontiers in oncology · 2020Review
- RANKL biology: bone metabolism, the immune system, and beyond.Inflammation and regeneration · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 13 institutions in 5 countries.
Shuan RaoInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Verena SiglInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Reiner Alois WimmerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Maria NovatchkovaInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Alexander JaisDepartment of Laboratory Medicine, Medical University Vienna, Vienna 1090, Austria.
Gabriel WagnerDepartment of Laboratory Medicine, Medical University Vienna, Vienna 1090, Austria.
Stephan HandschuhVetCore Facility for Research, University of Veterinary Medicine, Vienna 1220, Austria.
Iris UribesalgoInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Astrid HagelkruysInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Ivona KozieradzkiInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Luigi TortolaInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Roberto NitschInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Shane J CroninInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Michael OrthoferInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.
Daniel BranstetterDepartment of Pathology, Amgen, Inc., Seattle, Washington 98119, USA.
Jude CanonDepartment of Oncology Research, Amgen, Inc., Seattle, Washington 98119, USA.
John RossiDepartment of Molecular Sciences, Amgen, Inc., Seattle, Washington 98119, USA.
Manolo D'ArcangeloUniversity of Colorado Cancer Center, Aurora, Colorado 80045, USA.
Johan BotlingDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala 75185, Sweden.
Patrick MickeDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala 75185, Sweden.
Linnea La FleurDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala 75185, Sweden.
Karolina EdlundLeibniz Research Center for Working Environment and Human Factors, Dortmund 44139, Germany.
Michael BergqvistDepartment of Oncology, Gavle Hospital, Gavle 80187, Sweden.
Simon EkmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm 17177, Sweden.
Thomas LendlGregor Mendel Institute of Molecular Plant Biology (GMI), Vienna 1030, Austria.
Helmut PopperResearch Unit Molecular Lung and Pleura Pathology, Institute of Pathology, Medical University Graz, Graz 8036, Austria.
Hiroshi TakayanagiDepartment of Immunology, Tokyo University, Tokyo 108-8639, Japan.
Lukas KennerDepartment of Clinical Pathology, Medical University Vienna, Vienna 1090, Austria.
Fred R HirschUniversity of Colorado Cancer Center, Aurora, Colorado 80045, USA.
William DougallDepartment of Oncology Research, Amgen, Inc., Seattle, Washington 98119, USA.
Josef M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.ORCID 0000-0002-8194-3777
Institute of Molecular Biotechnology · ATAmgen (United States) · USUppsala University · SEUniversity of Colorado Cancer Center · USUniversity of Veterinary Medicine Vienna · ATGävle Hospital · SEGregor Mendel Institute of Molecular Plant Biology · ATKarolinska Institutet · SEMax Planck Institute for Metabolism Research · DEMedical University of Graz · ATMedical University of Vienna · ATTokyo Medical University · JPTU Dortmund University · DE
Funding
Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8MNCI NIH HHS P50 CA058187
Abstract
Lung cancer is the leading cause of cancer deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung cancer in women; however, the underlying mechanisms remain unclear. Here we report that the receptor activator of nuclear factor-kB (RANK), the key regulator of osteoclastogenesis, is frequently expressed in primary lung tumors, an active RANK pathway correlates with decreased survival, and pharmacologic RANK inhibition reduces tumor growth in patient-derived lung cancer xenografts. Clonal genetic inactivation of
Indexed as
Alveolar Epithelial CellsAnimalsCell RespirationCells, CulturedEnergy MetabolismFemaleGonadal Steroid HormonesHomeostasisHumansLungLung NeoplasmsMaleMiceMitochondriaNeoplastic Stem CellsProto-Oncogene Proteins p21(ras)Gonadal Steroid HormonesHras protein, mouseProto-Oncogene Proteins p21(ras)Receptor Activator of Nuclear Factor-kappa BTNFRSF11A protein, humanTnfrsf11a protein, mouseenergy homeostasislung cancerlung cancer stem-like cellsRANK
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.